U.S. FDA Approves EDURANT® PED (rilpivirine) for Certain Pediatric Patients Living with HIV-1
ViiV Healthcare Announces Data at CROI Indicating Efficacy of Cabenuva
GSK`s injectable HIV drug shows promise over daily pills
ViiV Healthcare receives approval from China’s NMPA for Vocabria
Janssen`s Rekambys (Rilpivirine) Receives Approval in Europe
ViiV Healthcare Announces Positive Data Demonstrating Long-acting Injectable Cabenuva (cabotegravir, rilpivirine) is as Effective as Daily Oral Biktarvy (BIC/FTC/TAF) for the Treatment of HIV-1
Lupin's Generic Dolutegravir Sodium and Rilpivirine Receives Approval in the U.S.
If you purchased Atripla®, Biktarvy®, Complera®, Descovy®, Evotaz®, Genvoya®, Odefsey®, Prezcobix®, Stribild®, Symtuza®, Truvada®, or Viread®, a class action lawsuit may affect your rights. If you are a member of one or both classes, your legal rights will be affected whether you act or don't act, so please read this notice carefully. You must decide whether to remain a member of the class(es) or to exclude yourself from the class(es).
Four decades after the start of the HIV epidemic, patients whose virus has become resistant to multiple therapies have a new treatment option.nFour decades after the start of the HIV epidemic, patients whose virus has become resistant to multiple therapies have a new treatment option.
LONDON--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer and Shionogi as shareholders, today presented findings from the CARISEL study (Cabotegravir And Rilpivirine Implementation Study in European Locations). The study, which evaluated the perspectives of people living with HIV and healthcare teams through surveys and interviews in addition to evaluating clinical effectiveness, demonstrated that ViiV Healthcare’s Vocabria (cabotegravir injection) and Janssen Pharmaceutical Companies of Johnson and Johnson’s Rekambys (rilpivirine long-acting injectable suspension) was successfully implemented across a range of European healthcare settings.1 The 12-month findings from the implementation study of the first and only complete long-acting regimen for HIV treatment were presented today at the 30th HIV Glasgow Conference being held in Glasgow, Scotland and virtually, from 23 – 26 October.